Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics

American Heart Journal

Volumn 156, Issue 6, 2008, Pages 1074-1079

  Ratner, Robert E ^a   Cannon, Christopher P ^b   Gerstein, Hertzel C ^c   Nesto, Richard W ^d   Serruys, Patrick W ^e   van Es, Gerrit Anne ^f   Kolatkar, Nikheel S ^g   Kravitz, Barbara G ^g   Zalewski, Andrew ^g   Fitzgerald, Peter J ^h  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f CARDIALYSIS   (Netherlands)

^g GLAXOSMITHKLINE   (United States)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLIPIZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FEMALE; GEOGRAPHIC DISTRIBUTION; GLUCOSE METABOLISM; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 56349123666     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2008.07.025     Document Type: Article

References (29)

1. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
2. Pan W.H., Cedres L.B., Liu K., et al. Relationship of clinical diabetes and asymptomatic hyperglycemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123 (1986) 504-516
3. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
5. Gaede P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358 (2008) 580-591
6. Ricciardi M.J., Meyers S., Choi K., et al. Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events. Am Heart J 146 (2003) 507-512
7. von Birgelen C., Hartmann M., Mintz G.S., et al. Relationship between cardiovascular risk as predicted by established risk scores versus plaque progression as measured by serial intravascular ultrasound in left main coronary arteries. Circulation 110 (2004) 1579-1585
8. Nissen S.E., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. J Am Med Assoc 292 (2004) 2217-2225
9. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. J Am Med Assoc 291 (2004) 1071-1080
10. Okazaki S., Yokoyama T., Miyauchi K., et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation 110 (2004) 1061-1068
11. Schartl M., Bocksch W., Koschyk D.H., et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 104 (2001) 387-392
12. Takagi T., Yoshida K., Akasaka T., et al. Intravascular ultrasound analysis of reduction in progression of coronary narrowing by treatment with pravastatin. Am J Cardiol 79 (1997) 1673-1676
13. Kahn S.E., Haffner S., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
14. Haffner S.M., Greenberg A.S., Weston W.M., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
15. Natali A., Baldeweg S., Toschi E., et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27 (2004) 1349-1357
16. Derosa G., Gaddi A.V., Piccinni M.N., et al. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome. Pharmacotherapy 25 (2005) 637-645
17. Kelly A.S., Thelen A.M., Kaiser D.R., et al. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. Vasc Med 12 (2007) 311-318
18. Qayyum R., and Adomaityte J. A meta-analysis of the effect of thiazolidinediones on blood pressure. J Clin Hypertens 8 (2006) 19-28
19. Nissen S.E., Nicholls S.J., Wolski K., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. J Am Med Assoc 299 (2008) 1561-1573
20. De Winter S.A., Hamers R., Degertekin M., et al. Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: the intelligate method. Catheter Cardiovasc Interv 61 (2004) 84-94
21. Rodriguez-Granillo G.A., Vos J., Bruining N., et al. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study). Am J Cardiol 100 (2007) 159-163
22. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. J Am Med Assoc 295 (2006) 1556-1565
23. Boccara F., and Cohen A. Interplay of diabetes and coronary heart disease on cardiovascular mortality. Heart 90 (2004) 1371-1373
24. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
25. Rosmarakis E.S., and Falagas M.E. Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J 154 (2007) 144-150
26. Bhatt D.I., Chew D.P., Grines C., et al. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization-results of the PPAR Study. Am Heart J 154 (2007) 137-143
27. Nicholls S.J., Sipahi I., Schoenhagen P., et al. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat Rev Drug Discov 5 (2006) 485-492
28. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41 4 Suppl S (2003) 15S-22S
29. Vaina S., and Stefanadis C. Detection of the vulnerable coronary atheromatous plaque. Where are we now?. Int J Cardiovasc Intervent 7 (2005) 75-87